Close Menu

NEW YORK (GenomeWeb) – Canaccord and William Blair have upgraded their ratings on Quidel’s shares to Buy and Outperform, respectively, based on its acquisition of Alere's Triage B-type natriuretic peptide assay and cardiovascular and toxicology diagnostic assets, announced yesterday.

Quidel agreed to pay $400 million for the assets and $40 million in contingent consideration. It expects the deal to close by Sept. 20.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.